Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the role of topical Ivermectin 1% cream and its effect on protease and
antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on
the skin) in rosacea. This is a single-site 16-week open-label study at University of
California, San Diego. The investigators will do this by first measuring serine protease
activity and cathelicidin and skin microbiome of all subjects. All subjects will receive
Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks.
Participants will return for monthly visits during which their clinical symptoms of facial
redness and number of facial papules will be scored, and they will have repeat tape stripping
and/or skin swabs. At the end of the study, tape strips and skin swabs will be analyzed to
determine serine protease activity and skin microbiome of participants at each of their
visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at
changes in serine protease activity and LL-37 expression and skin microbiome over time, and
they will also determine whether or not these changes correlate with disease severity.